Pacira BioSciences, Inc. (PCRX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$36.40+0.03%
Close 2026-11-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
QuarterlyIQ Insights · PCRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 11.7% |
| Our one-year growth estimate | diamond | 5.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 6.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 8 industry peers
PCRX — divestiture
Dated 2026-06-30
Entry Into a Material Definitive Agreement. On June 28, 2026, Pacira BioSciences, Inc. (the “Company”) and Pacira CryoTech, Inc., the Company’s wholly owned subsidiary (the “Subsidiary”), entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with Zimmer, Inc. (the “Purchaser”), a subsidiary of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”). Pursuant to the Purchase Agreement, the Company has agreed to divest to the Purchaser (i) all of the issued and outstanding capital…
Why it matters: Pacira set full-year revenue guidance of $735 million to $760 million after selling iovera. Q3 results test progress toward that range.
Watch forOn the November 5 call, Pacira keeps its $735 million to $760 million full-year revenue range. It reports revenue that supports reaching that range.
Also watch forPacira cuts the $735 million lower end, or Q3 results and new guidance put full-year revenue below $735 million.
Why it matters: Pacira’s 2026 margin range is below its 2025 range of 80% to 82%. Q3 results can show whether the lower range holds.
Watch forPacira keeps its 77% to 79% full-year margin range and reports Q3 results consistent with that range.
Also watch forPacira lowers the 77% margin floor, or reports results that put full-year margin below 77%.
Why it matters: The data will show whether this knee gene therapy merits further study. Pacira said the results were due by the end of 2026.
Watch forPacira reports Part A results by December 31, 2026. It says the study met its main goal.
Also watch forPacira reports that the study missed its main goal, or that results will come after December 31, 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$102 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $345 loss on $10,000 · 3.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,819 loss on $10,000 · 28.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.